Most Popular in:
New in Physiology (page 67 of 71)
Marathon runners can be proud of their stamina, but all that time outdoors boosts their risk of skin cancer, including the potentially deadly malignant melanoma, according to a study in the Archives of Dermatology.
"We are the first to report this," researcher Christina M. Ambros-Rudolph, MD, tells WebMD in an e-mail interview.
Ambros-Rudolph is a consultant dermatologist at the Medical University of Graz, Austria.
She and her co-researchers, all runners, conducted the study after caring for eight ultra-marathon runners with malignant melanoma over the past decade.
Comparing Runners and Nonrunners
In the study, the researchers evaluated 210 marathon runners, men and women, aged 19 to 71.
They compared the runners' skin cancer risks with those of 210 men and women matched for age and gender who were not long-distance runners.
All participants underwent a skin cancer exam and answered questions about personal and family skin cancer history, as well as changes in skin lesions, sunburn history, sun sensitivity, and physical characteristics such as skin and eye color.
Even though more of the nonrunners had higher sun sensitivity, reflected by their light eyes and sensitive skin types, the runners had more atypical moles and more lesions called solar lentigines—often called "liver spots"—which are associated with a higher risk of malignant melanoma.
Not surprisingly, the more intense the training regimen, the more likely a marathon runner was to have the lesions and moles, Ambros-Rudolph found. While some runners logged about 25 miles a week, others put in more than 44 miles a week.
No lesions suggestive of malignant melanoma were found, but 24 marathoners and 14 from the control group were referred to dermatologists to evaluate growths that looked like nonmelanoma skin cancers (such as basal cell and squamous cell skin cancers).
What's behind the increased risk?
The study reflects what dermatologists see in practice, says Diane Madfes, MD, a New York City dermatologist and a spokeswoman for the Skin Cancer Foundation.
Among her patients who are long-distance runners, Madfes says she has seen many cases of abnormal moles as well as nonmelanoma cancers, though not much melanoma, she says.
Greater ultraviolet exposure, of course, is one explanation for the increased risk, say the Austrian researchers.
Nearly 97% of the runners studied said they wore running shorts and short-sleeved or sleeveless shirts.
Only 56% said they regularly use sunscreen; nearly 2% never do.
Also, long-term, high-intensity exercise suppresses the immune system, the Austrian researchers write. They note that patients who have undergone transplants and had immunosuppressive therapy have an increase in all types of skin cancers.
Reducing the Risk
Ambros-Rudolph advises runners to cover up, train when sunlight exposure is less intense, and slather on the sunscreen—in spray or lotion form. An SPF of 15 or higher is recommended.
The type of product preferred varies by gender, Ambros-Rudolph has observed. "Men usually hate using lotions, and sprays are quicker to apply and easier to apply on hairy skin, while women often suffer from dry skin and love lotions that moisturize at the same time."
Reapplying a water-resistant sunscreen every two hours is important, adds Madfes.
She suggests runners consider bicycling attire, especially the long-sleeved shirts made of newer wicking materials that draw away moisture from sweat.
About 62,000 new cases of malignant melanoma are expected this year in the U.S., along with more than a million nonmelanoma skin cancers, says the American Cancer Society.
About 8,000 are expected to die this year from malignant melanoma; nonmelanoma skin cancers will claim about 2,000 lives.
By Kathleen Doheny, WebMD Medical News, November 20, 2006
The Australian government has launched an advertising campaign aimed at raising awareness among teenagers of the dangers of skin cancer.
A graphic series of TV ads shows that overexposure to the sun can cause skin cancer in people of all ages.
Australia's chief medical officer, John Horvath, told the Australian Broadcasting Corporation many teenagers are unaware of the facts about skin cancer and they are too young to remember earlier public education campaigns.
"You have to get the message out there again and dispel some of the myths that, 'if you don't get sunburned you'll be all right,' or that a suntan or an olive skin protects you. None of those things are true," Horvath said.
United Press International, November 19, 2006
Finally, there may be something duct tape can't fix: the lowly wart.
Despite claims in an earlier study, covering warts with duct tape may not make them vanish faster after all, say Dutch researchers, including Maastricht University's Marloes de Haen, MD.
The Dutch researchers had heard of a study in which duct tape showed promise as a home remedy for warts -- the skin infections caused by the human papillomavirus.
So de Haen's team conducted their own study, now published in the Archives of Pediatrics & Adolescent Medicine.
The study included 103 Dutch kids aged 4-12 who had at least one wart.
For six weeks, half the children wore duct tape over one of their warts, while the rest wore corn pads over one of theirs.
Once a week, the children uncovered the wart, soaked it in warm water for five minutes, then rubbed the wart gently with a pumice stone.
During the study, the warts covered by duct tape were only slightly more likely to heal than those covered by corn pads.
"After six weeks, the wart had disappeared in 16% of the children in the duct tape group, compared with 6% in the placebo [corn pad] group," the researchers write.
That margin was so slim that it may have been due to chance, de Haen's team says.
Most of the kids in the duct tape group -- 81% -- said the tape didn't stick well to their skin. And 15% reported skin irritations, including rashesrashes.
"Further research with longer follow-up would only be useful with a tape that is better sticking," write the researchers.
By Miranda Hitti, WebMD Medical News, November 8, 2006
Plagued by poison ivy allergy? It might be possible to coax the body to build up immunity to poison ivy.
That news comes from researchers including Mary Morris, MD, of Allergy Associates of La Crosse in La Crosse, Wis.
They studied 115 people with a history of severe skin reactions to poison ivy who were treated at their clinic over the past 15 years.
The treatment was a small amount of poison ivy extract placed under the tongue. The goal was to train the body's immune system not to overreact to poison ivy.
The patients took skin tests to see if the treatment helped.
Those tests showed that after treatment, patients had a much higher threshold for allergic skin reactions to poison ivy.
Ninety percent of the patients said they had "far fewer" skin reaction episodes. Patients who said they still got skin rashesrashes reported milder rashes that were quicker to heal than before treatment.
Further tests are needed. If those tests go well, the treatment may help people whose jobs and hobbies expose them to poison ivy, the researchers note.
The findings were presented in Philadelphia at the American College of Allergy, Asthma, and Immunology's annual scientific meeting.
By Miranda Hitti, WebMD Medical News, November 14, 2006
The Abbott Laboratories drug Humira (adalimumab) has been given expanded approval by the U.S. Food and Drug Administration to slow structural joint damage in people with psoriatic arthritis. The condition affects people who have skin psoriasis.
Humira was initially approved for overall treatment of psoriatic arthritis in October 2005. It's also been sanctioned to treat moderate-to-severe rheumatoid arthritis, and an inflammatory disease of the spine called ankylosing spondylitis.
Psoriatic arthritis combines symptoms of arthritis—including joint pain and inflammation—with those of psoriasis, including painful red lesions on the skin. Clinical testing on 313 people who hadn't responded to NSAID therapy found that people given Humira had significantly less joint damage than study participants who took a non-medicinal placebo, Abbott said in a statement.
People who took Humira also demonstrated increased ability to perform daily functions such as getting dressed, walking, and climbing stairs, the company said.
HealthDay News, November 14, 2006
The bumps (papules) and pimples (pustules) of rosacea, a poorly-understood facial disorder affecting an estimated 14 million Americans, may be the result of an allergy-like reaction to environmental and emotional triggers, according to new study results presented at the National Rosacea Society (NRS) research workshop during the annual meeting of the Society for Investigative Dermatology and reported in Rosacea Review.
"We are very excited about these findings because they may provide the basis for improving the treatment and management of this condition," said Dr. Richard Gallo, chief of the division of dermatology at the University of California-San Diego and lead investigator of the NRS-funded study. "By defining the process leading to the inflammation, new medications might be developed to block these effects."
Dr. Gallo explained that when the normal immune system is faced with any of a broad range of potential dangers—such as sun exposure, emotional stress, heat and spicy foods, among many others—receptors recognize potential threats and protect the body by prompting the production of protective substances that isolate and neutralize any harmful effects. With rosacea, however, these protective substances turn the body on itself like overzealous guards, leading to inflammation.
Using advanced mass spectrometry technology to analyze the biochemical composition of proteins in rosacea patients, the researchers discovered an abnormality in the production of protective molecules known as cathelicidins, Dr. Gallo said. In normal patients, the cathelicidins are found in a form that is inactive and would not lead to bumps and pimples. In rosacea patients, the forms of cathelicidins are different and lead to skin inflammation. The cause of this abnormality in cathelicidins seems to be due to an equally important problem in rosacea—an overabundance of yet another substance, called kallikrein, which can spur dormant cathelicidins into action.
"It appears that the combination of these two substances at abnormally high levels is a double whammy for rosacea patients," Dr. Gallo noted.
The researchers recently completed the picture when they were able to demonstrate that this process is linked to the actual formation of rosacea signs and symptoms. The skin of mice injected with the cathelicidins found in rosacea patients showed a dramatic inflammatory response—including bumps and pimples—while mice injected with normal cathelicidins showed no inflammation, either visually or under a microscope.
"The next step is to test these findings in human subjects through various therapeutic interventions," Dr. Gallo said. "As we gain a thorough understanding in humans, we can look for new medications that block this process in order to treat or prevent the inflammation associated with rosacea."
Rosacea is a chronic disorder that primarily affects the cheeks, nose, chin or forehead, and is often characterized by flare-ups and remissions. It typically begins as a flushing or redness that comes and goes, and visible blood vessels may also appear. Inflammatory bumps and pimples often develop, and in severe cases, the nose may become swollen and enlarged from excess tissue.
In addition to long-term medical therapy to bring the condition under control and maintain remission, patients are advised to keep a diary to identify and avoid lifestyle and environmental factors that may affect their individual cases. Some of the most common rosacea triggers include sun exposure, emotional stress, hot or cold weather, wind, heavy exercise, alcohol, hot baths and spicy foods.
A new combination treatment offers hope to people who have the blistering, potentially fatal skin disease known as pemphigus vulgaris.
By combining the cancer-fighting drug rituximab with intravenous immune globulin, Harvard doctors have discovered a therapy that can effectively treat people with cases of pemphigus vulgaris that haven't responded to other treatments.
"We got a home run with this combination," said study co-author Dr. Marshall Posner, medical director of the head and neck oncology program at the Dana-Farber Cancer Institute and Harvard Medical School.
"These patients were extremely ill and on multiple medications," he said. "This therapy resulted in complete eradication of the disease for nine patients." The remaining two patients in the study required additional doses of the treatment before they, too, went into remission. All of those involved in the study had sustained remissions, some as long as 37 months, by the end of the study.
Results of the study are published in the Oct. 26 issue of the New England Journal of Medicine.
Pemphigus vulgaris is a rare autoimmune disease that causes the skin cells to stop adhering to one another. Blisters and lesions form, usually beginning in the mouth and then spreading to the skin.
"Before the discovery of corticosteroids, it was fatal within five years. People lost the surface of their skin, and died horrible deaths," explained Dr. John Stanley, chairman of the department of dermatology at the University of Pennsylvania School of Medicine. "This is an instructive disease about the power of the immune system. While it's usually used for good, it can actually destroy you."
Stanley co-authored a review article in the same issue of the journal about pemphigus and other dermatological diseases.
Currently, the first line of treatment for this devastating skin condition is prednisone, a corticosteroid. While it's often an effective treatment, it has numerous side effects that can be serious, so people generally can't stay on high doses for a long time. Other medications used are immune-suppressing agents that also carry the risk of serious side effects, such as infection.
Posner said most deaths from pemphigus occur as a result of immune-system suppression. But without suppressing the immune system, people with pemphigus would continue to develop blisters and erosions in their skin, giving bacteria an easy entry into the body.
Another treatment option is intravenous immune globulin. This option is usually reserved for those who don't respond to the other treatment options. Stanley said scientists aren't sure how this therapy works, but it may be that it replaces the immune-system antibodies that are attacking the skin cells with healthy antibodies.
For most people, these treatments options have proved lifesaving, and people with the disease often do well, said Stanley.
However, there are people who don't respond to any of the currently available treatments. And, the 11 people treated in the new Harvard study fell into that category. None of the available treatments had worked for them, and the disease was covering more than 30 percent of their body's surface area.
Each study volunteer received two cycles of rituximab weekly for three weeks. During the fourth week, they received a dose of intravenous immune globulin. Then, they received monthly infusions of both rituximab and IV immune globulin for four months.
During the initial treatment, nine of the 11 study participants went into remission for an average of 32 months. The remaining two required additional treatments about six months after treatment, but subsequently went back into remission.
While previous research on rituximab has sometimes found serious side effects, such as allergic reaction, Posner said there were virtually no side effects seen in this trial.
He said he thinks this drug combination would likely be helpful in less severe cases of pemphigus vulgaris, and he added that it could potentially be useful for treating other autoimmune diseases, such as rheumatoid arthritis, systemic lupus and type 1 diabetes.
"This therapy offers hope for this disease, and it could lead the way to treatment for other diseases that have a big impact on people's lives -- it needs to be investigated in other diseases so we can see how it works in other situations," Posner said.
Stanley said he doubted that rituximab would become a first-line treatment for pemphigus vulgaris anytime soon because the medication is quite costly and insurance companies would likely balk at paying for an expensive drug that isn't FDA approved specifically for treating pemphigus. The problem, he added, is that because pemphigus is so rare, it would be difficult to conduct a large enough trial to get such approval.
But, Posner suggested that while the rituximab/immune globulin combination treatment is more expensive initially, a cost analysis comparing all of the costs, including hospitalizations, might find the combination treatment is the cheaper alternative in the long run.
By Serena Gordon, HealthDay Reporter, October 26, 2006
By: Heather Woolery-Lloyd, MD
Discover the unique skin care challenges of various ethnic skin types and about some treatment options.
The FDA has approved a new drug to treat a rare and slow-growing type of skin cancer.
The agency approved Zolinza capsules for the treatment of cutaneous T-cell lymphoma (CTCL), a type of lymphoma that affects the skin.
The drug is approved for treatment when the disease gets worse, persists, or comes back during or after treatment with other medicines.
Researchers say about three in a million people are diagnosed with the skin cancer each year, mostly middle-aged men.
Zolinza was approved as part of FDA's Orphan Drug program, which offers companies financial incentives to develop medicines for diseases that affect fewer than 200,000 Americans a year.
Benefits and Risks
The safety and effectiveness of Zolinza were evaluated in two clinical trials involving 107 people with CTCL, who received the drug after their disease came back or other treatments had failed.
Of patients receiving the drug, 30% saw improvement, with the benefit lasting an average of 168 days.
The most common serious side effects of Zolinza were blood clots in the lungs (pulmonary embolism), dehydration, deep vein thrombosis (blood clots in deep veins) and anemia.
Other side effects included diarrhea, nausea, anorexia, vomiting, constipation, fatigue, chills, and taste disorders.
The drug has not been studied in pregnant women, but animal studies suggest Zolinza may harm the fetus if used during pregnancy.
Zolinza is manufactured by Pantheon Inc. for Merck & Co. Inc.
By Jennifer Warner, WebMD Medical News, October 11, 2006
Women's skin ages faster than men's, suggests a study that used an experimental laser device to measure skin damage.
Researchers in Germany used the device to determine collagen and elastin levels beneath the skin's surface. Collagen and elastin are the proteins responsible for the elasticity, tone, and texture of skin, and levels typically decline with age.
There is no good way to assess skin, as measured by collagen and elastin composition, short of removing skin and analyzing it in a lab.
The laser procedure shows promise for making the process a whole lot simpler. That could one day help consumers better evaluate the effectiveness of the antiaging skin products they buy, researcher Martin Johannes Koehler, of Germany's Schiller University, tells WebMD.
"Some cosmetics are thought to change the content of collagen to the skin, but until now to measure that you had to cut out a piece of skin," he says.
Multiphoton Laser Imaging
The search for a noninvasive test to measure damage to the skin from sun exposure and aging is the Holy Grail of the cosmetics industry.
But proving that a skin cream that promises to turn back the clock really is worth $100 an ounce is only one potential application for the experimental laser technique, Koehler says.
It may also prove useful for evaluating skin diseases like that seen in, which is a serious autoimmune disease, as well as a skin complication that can occur in transplant recipients, known as graft vs. host disease.
Koehler and colleagues used the technique, called multiphoton laser imaging, on the inner forearms of seven women and 11 men between the ages of 21 and 84.
The researchers used the information gathered from the imaging to develop an aging index of the dermis, an inner layer of the skin. Skin aging was more evident in women than in men of similar age. It was most marked in older women who had been through.
The researchers wrote that menopause-related declines in the sex hormones estrogen and progesterone might explain this acceleration in skin aging.
More Study Needed
But they added that more research is needed to confirm the finding that men and women's skin ages at different rates. The researchers also note that studies comparing their aging index measurements need to be compared to established measures such as skin surface hydration and wrinkle number and depth.
The study is published in the Oct. 1 issue of the journal Optics Letters.
Cosmetic dermatologist Eliot Battle, MD, tells WebMD that the laser procedure is one of several promising experimental techniques that could help clinicians more easily diagnose and treat skin diseases.
"Diagnostic tools like this have been used in every area of medicine, but they are only beginning to be used in dermatology," he says. "This [technique] is an attempt to use the latest and greatest in laser imaging, but much more research is needed. This is just the very beginning of what could be an exciting journey."
SOURCES: Koehler, M.J. Optical Letters, Oct. 1, 2006; vol 31: pp 2879-2881. Martin Johannes Koehler, department of dermatology and allergology, Friedrich Schiller University, Jena, Germany. Eliot Battle Jr., MD, cosmetic dermatologist and laser surgeon, Cultura Cosmetics Medical Spa, Washington, D.C.
By Salynn Boyles, WebMD, October 4, 2006